Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux

Status and phase

Completed

Phase 3

Conditions

HIV Risk

Treatments

Drug: Genvoya

Study type

Interventional

Funder types

NETWORK

Industry

Identifiers

NCT02998320

GEFR1044015

Details and patient eligibility

About

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks

Full description

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide (E/C/F/TAF) for four Weeks.

Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Cobicistat is a selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A subfamily. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue àf 2'-dexicytidine. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue).

Enrollment

101 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

an age above 18 years
consultation within 48 hours following a risk of HIV transmission (blood or sexual contact)
indication for HIV post-exposure prophylaxis (according to French guidelines)
person able to understand the nature of the study
person who signed his consent form to participate in the study

Exclusion criteria

person exposed to HIV risk from person infected by HIV, whose therapeutic history justifies the prescription of another combination of antiretroviral drugs
contraindications to the prescription of Genvoy
other medical contraindications
person infected by hepatitis B virus
pregnant or lactating woman